MolMed Shareholders’ Meeting approves the Financial Statements 2012 and appoints members of Board of Directors and Board of Statutory AuditorsMeeting of the new Board of Directors: appointment of the Chief Executive Officer and of the members of the Board Committees

1. MolMed: outcome of Shareholders' meeting and first
meeting of new Board of Directors
Molmed Shareholders' Meeting approves the Financial Statements 2012 and
appoints members of Board of Directors and Board of Statutory Auditors
Meeting of the new Board of Directors: appointment of the Chief Executive
Officer and of the members of the Board Committees
The Shareholders’ Meeting of MolMed S.p.A. (MLM.MI), chaired by Professor
Claudio Bordignon, met today to resolve upon the items of the agenda.
Item 1: approval of the Statutory Financial Statements for year 2012
Item 2: appointment of the members of the Board of Directors
Item 3: appointment of the members of the Board of Statutory
Auditors
Item 4: resolution on Section I of the Report on remuneration
Meeting of the new Board of Directors
Upon closure of the Meeting, the newly appointed Board of Directors met and
approved the appointment of the Chief Executive Officer and of the members
of the Board’s internal Committees.
Professor Claudio Bordignon was confirmed as Chief Executive Officer.
The Board’s internal Committees are composed as follows:

2. • Committee for control and risks: Mario Masciocchi (Chairman), Raffaella
Ruggiero, Gianluigi Fiorendi;
• Remuneration Committee: Raffaella Ruggiero (Chairman), Marco Bregni,
Sabina Grossi;
• Committee for transactions with related parties: function assigned
permanently to the Committee for control and risks, in some cases with
the participation of the third independent Director - as per the
Procedures on transactions with related parties published on MolMed’s
website (www.molmed.com)
The Board of Directors also verified the requirements of independence,
pursuant to Article 148 of the Consolidated Text of Finance (TUF) and to the
Code of conduct, of Directors Mario Masciocchi, Raffaella Ruggiero and Marco
Bregni.
The independent Director Mario Masciocchi was appointed to the office of Lead
Independent Director. Claudio Bordignon, Marina Del Bue and Germano
Carganico are executive Directors.
The curricula vitae of the Board members are available to the public (in Italian)
at MolMed’s premises and on MolMed’s website (www.molmed.com), section
“Investors”, page “Shareholders’ information/Shareholders’ Meetings/22 April
2013”.
The Directors Marina Del Bue and Alfredo Messina directly hold shares of
MolMed S.p.A.: Marina Del Bue holds 496,169 shares and Alfredo Messina
holds 623,302 shares.
This press release is written in compliance with public disclosure
obligations established by CONSOB (Italian securities & exchange
commission) resolution no. 11971 of 14 May 1999, as subsequently
amended.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development
and clinical validation of
novel anticancer therapies. MolMed’s pipeline includes two antitumour
therapeutics in clinical development: TK, a cell-based therapy enabling bone
marrow transplants from partially compatible donors, in absence of post-
transplant immune-suppression, in Phase III in high-risk acute leukaemia;
NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural

3. mesothelioma and in Phase II in six more indications: colorectal, lung (small-
cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas.
MolMed also offers top-level expertise in cell and gene therapy to third parties
to develop, conduct and validate projects from preclinical to Phase III trials,
including scale-up and cGMP production of clinical-grade viral vectors, and
manufacturing of patient-specific genetically engineered cells. MolMed is
headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The
Company’s shares are listed on the main market (MTA) of the Milan Stock
Exchange. (Ticker Reuters: MLMD.MI)
Fonte: MolMed